

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

January 6, 2026

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Stock Exchange Disclosure in relation to Outcome of Board Meeting, by Biocon Limited dated January 5, 2026

Please find attached the Stock Exchange Disclosure in relation to Outcome of Board Meeting of Biocon Limited, submitted by Biocon Limited to BSE and NSE at India, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited**Akhilesh
Nand**Digitally signed by
Akhilesh Nand
Date: 2026.01.06
11:17:51 +05'30'

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/152

January 05, 2026

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – Biocon

Dear Sir/Madam,

Subject: Acquisition of equity shares of Biocon Biologics Limited and allotment of equity shares of Biocon Limited (the “Company”) on a preferential basis

This is further to our intimation dated December 06, 2025 with respect to the outcome of the board meeting held on December 06, 2025, whereby the Board of Directors of the Company (“**Board**”) had approved: (a) the acquisition of equity shares of Biocon Biologics Limited (“**BBL**”), an unlisted material subsidiary of the Company; and (b) the issuance and allotment of equity shares of the Company on a preferential basis in dematerialised form in accordance with Chapter V of the SEBI (Issue of Capital Disclosure Requirements) Regulations, 2018 (“**Preferential Issue**”).

Please note the following updates with respect to the above:

- Following the extra-ordinary general meeting of the shareholders of the Company held on December 31, 2025, the Company has today i.e. on January 05, 2026:
- completed acquisition of 26,19,17,480 equity shares of BBL from (a) Mylan Inc. (“**Mylan**”); (b) Serum Institute Life Sciences Private Limited; (c) Tata Capital Growth Fund II; and (d) Activ Pine LLP (collectively referred as “**Allotees**”), and
 - pursuant to the in-principle approval issued by the National Stock Exchange of India Limited and BSE Limited dated December 31, 2025, issued and allotted 17,12,79,553 equity shares of the Company of the face value of Rs. 5/- each, fully paid-up, on a preferential basis in dematerialised form to the Allotees, as consideration for the acquisition described at limb (i) above, at an issue price of Rs. 405.78 per equity share pursuant to the approval of the Fund Raising Committee of the Company in accordance with the terms of the share swap and purchase agreements entered into with the Allotees, as per details given below:

Sl. No.	Name of the Allottee	Category	No. of BBL equity shares acquired	No. of equity shares allotted by the Company	Post allotment shareholding in the Company
---------	----------------------	----------	-----------------------------------	--	--

2.	Serum Institute Life Sciences Private Limited		7,89,02,725	5,54,48,765	3.68%
3.	Tata Capital Growth Fund II		88,30,456	62,05,589	0.41%
4.	Activ Pine LLP		2,51,27,315	1,76,58,180	1.17%
	TOTAL		26,19,17,480	17,12,79,553	11.36%

The equity shares allotted shall rank pari-passu, in all respects, with the existing equity shares of the Company.

Consequent to the aforesaid allotment, the issued, subscribed and paid-up equity share capital of the Company stands increased from Rs. 6,68,48,18,175/- comprising of 1,33,69,63,635 fully paid-up equity shares of the Company, having face value of Rs. 5/- each to Rs. 7,54,12,15,940/- comprising of 1,50,82,43,188 fully paid-up equity shares of the Company, having face value of Rs. 5/- each.

- Out of the acquisition of balance 14,36,69,382 equity shares of BBL from Mylan for cash consideration of USD 400 million as approved by the Board at its meeting held on December 06, 2025, the Company has today completed acquisition of 7,18,34,691 equity shares of BBL from Mylan against cash consideration of USD 200 million.

Post the aforesaid acquisition of 33,37,52,171 equity shares of BBL by the Company, the Company holds ~94% of the paid-up equity share capital of BBL on a fully diluted basis.

The meeting of the Fund Raising Committee commenced at 09:15 PM and concluded at 09:30 PM.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH
UMAKANT
SHANOE

Digitally signed by
RAJESH UMAKANT
SHANOE
Date: 2026.01.05
21:43:54 +05'30'

Rajesh U. Shanoy

Company Secretary and Compliance Officer

ICSI Membership Number: A16328